LEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend

Bulletin Express

08/07

Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:

• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026. • Considering the declaration of an interim dividend, if any. • Addressing other routine corporate matters.

The notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).

The forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1126980317"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126980317\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126980317?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126980317","market":"hk","top_or_hot":-1,"title":"LEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend","media":"Bulletin Express","content":"<p>Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:</p>\n<p>• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026.  \n• Considering the declaration of an interim dividend, if any.  \n• Addressing other routine corporate matters.</p>\n<p>The notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).</p>\n<p>The forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-07 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:</p>\n<p>• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026.  \n• Considering the declaration of an interim dividend, if any.  \n• Addressing other routine corporate matters.</p>\n<p>The notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).</p>\n<p>The forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02157","symbol_name":"乐普生物","start_time":0,"source_url":"","article_id":"1126980317","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126980317","pubTimestamp":1786101936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes: • Reviewing and approving the consolidated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02157":"乐普生物"},"translate_title":"乐普生物定于2026年8月19日召开董事会会议，批准2026年上半年业绩并评估中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":1},"content_text":"Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:\n• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026.  \n• Considering the declaration of an interim dividend, if any.  \n• Addressing other routine corporate matters.\nThe notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).\nThe forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}